Abstract
Drug development for neurodegenerative diseases such as Alzheimer’s disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developing fluorinated molecules and supramolecular assemblies.
This review focuses on the therapeutic potential of new fluorinated molecules, developed as active and selective agents for AD, to meet the desired pharmacokinetic/pharmacodynamic properties and BBB targeting. The methods to fluorinate organic molecules and a brief characterization of the mechanisms of AD progression and therapeutic approaches are described.
The paradigm of cell biology knowledge and fluorine biochemistry such as, organofluorine inhibitors of amyloid fibrilogenesis, is highlighted.
Keywords: Fluorine, Alzheimer’s disease, therapeutic drugs, beta amyloid, aggregation mechanism.
Current Pharmaceutical Design
Title:The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease
Volume: 21 Issue: 39
Author(s): Barbara Gomes, Joana A. Loureiro, Manuel A.N. Coelho and Maria do Carmo Pereira
Affiliation:
Keywords: Fluorine, Alzheimer’s disease, therapeutic drugs, beta amyloid, aggregation mechanism.
Abstract: Drug development for neurodegenerative diseases such as Alzheimer’s disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developing fluorinated molecules and supramolecular assemblies.
This review focuses on the therapeutic potential of new fluorinated molecules, developed as active and selective agents for AD, to meet the desired pharmacokinetic/pharmacodynamic properties and BBB targeting. The methods to fluorinate organic molecules and a brief characterization of the mechanisms of AD progression and therapeutic approaches are described.
The paradigm of cell biology knowledge and fluorine biochemistry such as, organofluorine inhibitors of amyloid fibrilogenesis, is highlighted.
Export Options
About this article
Cite this article as:
Gomes Barbara, Loureiro A. Joana, Coelho A.N. Manuel and do Carmo Pereira Maria, The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666150130120358
DOI https://dx.doi.org/10.2174/1381612821666150130120358 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases
Current Pharmaceutical Biotechnology A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters Age-Dependent Changes of the temporal Order - Causes and Treatment
Current Aging Science Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology The “Invisible Proteome”: How to Capture the Low-Abundance Proteins Via Combinatorial Ligand Libraries
Current Proteomics Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Microbial Interaction of Periodontopathic Bacterium Porphyromonas gingivalis and HIV-Possible Causal Link of Periodontal Diseases to AIDS Progression-
Current HIV Research Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research